Halozyme Therapeutics (HALO) Interest Expenses (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Interest Expenses data on file, last reported at $5.5 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $5.5 million, up 21.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (up 5.5% YoY), and the FY2025 annual result was $18.1 million, changed 0.17% from the prior year.
• Interest Expenses improved to $5.5 million in Q1 2026 per HALO's latest filing, from $4.9 million in the prior quarter.
• Over five years, Interest Expenses peaked at $7.5 million in Q3 2022 and troughed at $1.8 million in Q1 2022.
• A 5-year average of $4.6 million and a median of $4.5 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 328.39% in 2022, then sank 40.05% in 2023.
• A 5-year view of Interest Expenses shows it stood at $4.6 million in 2022, then gained by 14.22% to $5.2 million in 2023, then declined by 13.03% to $4.5 million in 2024, then climbed by 8.17% to $4.9 million in 2025, then grew by 12.16% to $5.5 million in 2026.
• Business Quant data shows HALO's Interest Expenses at $5.5 million in Q1 2026, $4.9 million in Q4 2025, and $4.3 million in Q3 2025.